Newsletter | November 11, 2026

11.11.26 -- Helping Staff Execute Clinical Trials

From Chaos To Clarity: A Founder's View From 30 Years In Drug Development

Webinar | TruTechnologies

Same workflows, higher stakes. A 30-year drug development veteran reveals how outdated sample handling puts trial outcomes at risk and what sponsors can do about it.

How ICH Oversight And AI Are Shaping The Future Of Clinical Trials

Webinar | PPD Clinical Research Business of Thermo Fisher Scientific

Explore how the new ICH E6 (R3) revisions are reshaping clinical trial oversight and examine how AI-driven tools like the Clinical Decision Suite can help sponsors enhance trial efficiency.

Using Technology To Reduce Monitoring Costs And Increase Quality

Webinar | CRIO

Join industry experts as they discuss how the true value of DDC lies not just in the cost of the technology itself but in the operational efficiencies it unlocks.

Your Biggest Unblinding Risk? Inexperienced Staff

Video | Korio

Protect study integrity by closing the gaps in IRT workflows. Learn why rushed communication and training lapses lead to accidental unblinding and how to safeguard your clinical data.

Protocol Builder And Informed Consent Builder Version 2.0

Video | BRANY

Built by research compliance experts, this platform streamlines the protocol-writing process through customizable templates, workflow tools, and collaboration support for research teams.

Leveraging Functional Service Providers For Drug Development Efficiency

Webinar | Worldwide Flex

Discover how functional service providers (FSPs) are reshaping clinical research by offering specialized expertise, flexible resources, and cost-effective solutions.

Qualified eSignature In Electronic Consent Systems

Webinar | IQVIA Technologies

This on‑demand session offers a clear, practical overview of the major eSignature types used in eConsent and explains when each is appropriate.

Who Is Actually Filling Out Your Feasibility Questionnaire?

Video | Clinical Leader

Nick Palumbo challenges sponsors to consider who is behind the enrollment projections they receive from sites. A feasibility response may come from someone who has thoroughly reviewed the protocol, or from someone making an educated guess with a financial interest in site selection.

Connect With Clinical Leader: